Long-term utilization of immunosuppression in organ transplant recipients (OTRs) leads to
decreased immune-mediated tumor surveillance and development of malignant tumors. A …

Immunosuppressed patients are at markedly increased risk of develo** cutaneous
malignancies compared with the general population. Although immunosuppression can …

Background The use of immunotherapies in the treatment of metastatic cancers has
significantly advanced oncology. However, due to safety concerns, solid organ transplant …

While the majority of cutaneous squamous cell carcinomas (cSCCs) can be treated
surgically, the additional work-up and treatments indicated for high-risk cSCC remain …

Invasive cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers in
white populations, accounting for 20% of all cutaneous malignancies. Overall, cSCC mostly …

Purpose Transplant recipients who develop cutaneous squamous cell carcinomas are at
high risk for multiple subsequent skin cancers. Sirolimus has been shown to reduce the …

Inhibitors of mTOR, including clinically available rapalogs such as rapamycin (Sirolimus)
and Everolimus, are gerosuppressants, which suppress cellular senescence. Rapamycin …

The pathogenesis of keratinocyte carcinoma following organ transplantation is multifactorial,
and recent evidence suggests a complex and often synergistic interplay between the …

Significant practice-changing developments have occurred in the care of heart
transplantation candidates and recipients over the past decade. This Canadian …

Use of immune checkpoint inhibitors (ICIs) in solid organ transplant recipients (SOTRs) with
advanced skin cancers presents a significant clinical management dilemma. SOTRs and …